The Prostate Centre
Welcome,         Profile    Billing    Logout  
 17 Trials 
13 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Chi, Kim N
EvoPAR-PR01, NCT06120491: Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

Recruiting
3
1800
Europe, Canada, Japan, US, RoW
Saruparib, AZD5305, Placebo, Abiraterone Acetate, Zytiga, Darolutamide, Nubequa, Enzalutamide, Xtandi
AstraZeneca
Metastatic Castration-Sensitive Prostate Cancer
01/28
04/31
NCT02905318: Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting
2
19
Canada
Palbociclib
Canadian Cancer Trials Group, Pfizer
Prostate Cancer
04/22
12/24
CCTG PR21, NCT04663997: 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer

Active, not recruiting
2
200
Canada
177Lu-PSMA-617, Docetaxel
Canadian Cancer Trials Group, Prostate Cancer Canada, Novartis Pharmaceuticals
Prostate Cancer
06/25
12/25
Joshua, Anthony
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
DASL-HiCaP, NCT04136353: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

Active, not recruiting
3
1100
Europe, Canada, US, RoW
Darolutamide, Placebo oral tablet, Luteinizing Hormone-Releasing Hormone Analog, External Beam Radiotherapy
University of Sydney, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Bayer, Cancer Trials Ireland, Canadian Cancer Trials Group, Memorial Sloan Kettering Cancer Center, Prostate Cancer Clinical Trials Consortium
Prostate Cancer
01/28
07/28
ENZA-p, NCT04419402: Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer

Active, not recruiting
2
162
RoW
Lu-PSMA, 177Lutetium -PSMA 617 also referred to as 177Lu-PSMA, Enzalutamide, Xtandi
Australian and New Zealand Urogenital and Prostate Cancer Trials Group, National Health and Medical Research Council, Clinical Trials Centre, Prostate Cancer Research Alliance, Endocyte, Astellas Pharma Inc
Metastatic Castration-Resistant Prostate Cancer
07/24
01/25
UpFrontPSMA, NCT04343885: In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy

Active, not recruiting
2
130
RoW
177Lu-PSMA-617, 177Lu-PSMA-617 also referred to as 177Lu-PSMA, Docetaxel, Taxotere (trade name)
Peter MacCallum Cancer Centre, Australia, Movember Foundation, Prostate Cancer Research Alliance, United States Department of Defense, Advanced Accelerator Applications, Australia's Nuclear Science and Technology Organisation (ANSTO), Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Australasian Radiopharmaceutical Trials network (ARTnet), Centre for Biostatistics and Clinical Trials (BaCT)
Metastatic Hormone Naive Prostate Cancer
04/24
04/24
SGNLVA-005, NCT04032704 / 2019-001946-17: A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Terminated
2
205
Europe, US, RoW
ladiratuzumab vedotin, SGN-LIV1A, pembrolizumab, Keytruda
Seagen Inc., Merck Sharp & Dohme LLC
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma
11/23
11/23
EVOLUTION, NCT05150236: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC

Active, not recruiting
2
93
RoW
177Lu-PSMA-617, 177Lutetium -PSMA 617 also referred to as 177Lu-PSMA, Ipilimumab, YERVOY, Nivolumab, OPDIVO
Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Prostate Cancer Foundation of Australia, Bristol-Myers Squibb, Advanced Accelerator Applications, University of Sydney
Prostatic Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Prostate Cancer, Neoplasms by Site, Neoplasms, Prostatic Disease
08/24
12/24
WOMBAT, NCT06594926: Working Out M0 Bipolar Androgen Therapy

Recruiting
2
69
RoW
Testosterone Enanthate, Primoteston Depot
Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Bayer, The George Institute, HMRI
Prostate Cancer
12/26
12/28
DECREASE, NCT04319783: Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA

Recruiting
2
70
RoW
Darolutamide, NUBEQA, Bayer HealthCare Pharmaceuticals Inc., Radiotherapy
Trans Tasman Radiation Oncology Group, Bayer, Peter MacCallum Cancer Centre, Australia
Advanced Prostate Carcinoma, Cancer of Prostate, PSA, Castrate Resistant Prostate Cancer
06/26
06/26
ENBolden-101, NCT04205227: ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors

Active, not recruiting
1/2
137
US, RoW
ENB003, Pembrolizumab, KEYTRUDA®, MK-3475
ENB Therapeutics, Inc, Merck Sharp & Dohme LLC
Cancer, Melanoma, Ovary Cancer, Pancreatic Cancer, Solid Tumor
01/26
03/26
NCT04109456: IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

Active, not recruiting
1
120
US, RoW
IN10018, BI 853520, Cobimetinib, Cotellic, Atezolizumab
InxMed (Shanghai) Co., Ltd.
Metastatic Melanoma
06/25
12/25

Download Options